Navigation Links
Transplanted brain cells in monkeys light up personalized therapy

MADISON For the first time, scientists have transplanted neural cells derived from a monkey's skin into its brain and watched the cells develop into several types of mature brain cells, according to the authors of a new study in Cell Reports. After six months, the cells looked entirely normal, and were only detectable because they initially were tagged with a fluorescent protein.

Because the cells were derived from adult cells in each monkey's skin, the experiment is a proof-of-principle for the concept of personalized medicine, where treatments are designed for each individual.

And since the skin cells were not "foreign" tissue, there were no signs of immune rejection potentially a major problem with cell transplants. "When you look at the brain, you cannot tell that it is a graft," says senior author Su-Chun Zhang, a professor of neuroscience at the University of Wisconsin-Madison. "Structurally the host brain looks like a normal brain; the graft can only be seen under the fluorescent microscope."

Marina Emborg, an associate professor of medical physics at UW-Madison and the lead co-author of the study, says, "This is the first time I saw, in a nonhuman primate, that the transplanted cells were so well integrated, with such a minimal reaction. And after six months, to see no scar, that was the best part."

The cells were implanted in the monkeys "using a state-of-the-art surgical procedure" guided by an MRI image, says Emborg. The three rhesus monkeys used in the study at the Wisconsin National Primate Research Center had a lesion in a brain region that causes the movement disorder Parkinson's disease, which afflicts up to 1 million Americans. Parkinson's is caused by the death of a small number of neurons that make dopamine, a signaling chemical used in the brain.

The transplanted cells came from induced pluripotent stem cells (iPS cells), which can, like embryonic stem cells, develop into virtually any cell in the body. iPS cells, however, derive from adult cells rather than embryos.

In the lab, the iPS cells were converted into neural progenitor cells. These intermediate-stage cells can further specialize into the neurons that carry nerve signals, and the glial cells that perform many support and nutritional functions. This final stage of maturation occurred inside the monkey.

Zhang, who was the first in the world to derive neural cells from embryonic stem cells and then iPS cells, says one key to success was precise control over the development process. "We differentiate the stem cells only into neural cells. It would not work to transplant a cell population contaminated by non-neural cells."

Another positive sign was the absence of any signs of cancer, says Zhang a worrisome potential outcome of stem cell transplants. "Their appearance is normal, and we also used antibodies that mark cells that are dividing rapidly, as cancer cells are, and we do not see that. And when you look at what the cells have become, they become neurons with long axons [conducting fibers], as we'd expect. They also produce oligodendrocytes that are helping build insulating myelin sheaths for neurons, as they should. That means they have matured correctly, and are not cancerous."

The experiment was designed as a proof of principle, says Zhang, who leads a group pioneering the use of iPS cells at the Waisman Center on the UW-Madison campus. The researchers did not transplant enough neurons to replace the dopamine-making cells in the brain, and the animal's behavior did not improve.

Although promising, the transplant technique is a long way from the clinic, Zhang adds. "Unfortunately, this technique cannot be used to help patients until a number of questions are answered: Can this transplant improve the symptoms? Is it safe? Six months is not long enough And what are the side effects? You may improve some symptoms, but if that leads to something else, then you have not solved the problem."

Nonetheless, the new study represents a real step forward that may benefit human patients suffering from several diseases, says Emborg. "By taking cells from the animal and returning them in a new form to the same animal, this is a first step toward personalized medicine."

The need for treatment is incessant, says Emborg, noting that each year, Parkinson's is diagnosed in 60,000 patients. "I'm gratified that the Parkinson's Disease Foundation took a risk as the primary funder for this small study. Now we want to move ahead and see if this leads to a real treatment for this awful disease."

"It's really the first-ever transplant of iPS cells from a non-human primate back into the same animal, not just in the brain," says Zhang. "I have not seen anybody transplanting reprogrammed iPS cells into the blood, the pancreas or anywhere else, into the same primate. This proof-of-principle study in primates presents hopes for personalized regenerative medicine."


Contact: Su-Chun Zhang
University of Wisconsin-Madison

Related biology technology :

1. Stem Cells Show Promise in Extending Transplanted Kidneys’ Survival Time
2. Magnet helps target transplanted iron-loaded cells to key areas of heart
3. NSBRI Funds Cerebrotech to Accelerate Development of Brain Monitoring Device
4. Study: Brain Imaging After Mild Head Injury/Concussion Can Show Lesions
5. Enhanced brain acetate metabolism may reward heavy drinkers
6. Ectopic eyes function without connection to brain
7. Blueprint for an artificial brain
8. Amarantus BioScience and Banyan Biomarkers to Present Poster of MANF Data at The 3rd Annual Traumatic Brain Injury Conference
9. Brain Research Foundation 2013 Scientific Innovations Awards To Dr. Jean Hebert and Dr. Brian Litt
10. Society for Brain Mapping and Therapeutics endorse President Obamas support for Human Brain Mapping research; nominating him for prestigious Pioneer in Healthcare Policy Award
11. Fighting disease deep inside the brain
Post Your Comments:
(Date:12/1/2015)... SAN DIEGO , Dec. 1, 2015 /PRNewswire/ ... that uses allogeneic stem cells for cardiovascular indications, ... clinical trial protocol based on recommendations from a ... leaders and its Scientific Advisory Board members ... boards analyzed preliminary Phase IIa safety and efficacy ...
(Date:12/1/2015)... Cepheid (Nasdaq: CPHD ) today announced ... Jaffray Healthcare Conference in New York City ... its outlook for the fourth quarter of 2015 and ... longer term business model expectations. John Bishop ... to be the fastest growing company of the major ...
(Date:11/30/2015)... ... 30, 2015 , ... Global Stem Cells Group ... from Central America and abroad for the first Iberoamerican Convention on Aesthetic Medicine, ... 2016. Testart will present and discuss new trends in anti-aging stem cell treatments, ...
(Date:11/30/2015)... MONTREAL , Dec. 1, 2015 /PRNewswire/ - BioAmber Inc. (NYSE: ... that it has joined the American Business Act on Climate ... economy that are standing with the Obama Administration to demonstrate ... for a strong outcome to the COP21 Paris ... . --> Sarnia, Canada . ...
Breaking Biology Technology:
(Date:10/29/2015)... Calif. , Oct. 29, 2015  The J. ... new report titled, "DNA Synthesis and Biosecurity: Lessons Learned ... the Department of Health and Human Services guidance for ... in 2010. --> ... it also has the potential to pose unique biosecurity ...
(Date:10/29/2015)... , Oct. 29, 2015  Connected health pioneer, ... driving the explosion of technology-enabled health and wellness, and ... new book, The Internet of Healthy Things ... sensors or smartphones even existed, Dr. Kvedar, vice president, ... of health care delivery, moving care from the hospital ...
(Date:10/27/2015)... , Oct. 27, 2015 In the present ... of concern for various industry verticals such as banking, ... to the growing demand for secure & simplified access ... ,sectors, such as hacking of bank accounts, misuse of ... equipment such as PC,s, laptops, and smartphones are expected ...
Breaking Biology News(10 mins):